Abstract-We present a fully automatic method for articular cartilage segmentation from magnetic resonance imaging (MRI) which we use as the foundation of a quantitative cartilage assessment. We evaluate our method by comparisons to manual segmentations by a radiologist and by examining the interscan reproducibility of the volume and area estimates. Training and evaluation of the method is performed on a data set consisting of 139 scans of knees with a status ranging from healthy to severely osteoarthritic. This is, to our knowledge, the only fully automatic cartilage segmentation method that has good agreement with manual segmentations, an interscan reproducibility as good as that of a human expert, and enables the separation between healthy and osteoarthritic populations. While high-field scanners offer high-quality imaging from which the articular cartilage have been evaluated extensively using manual and automated image analysis techniques, low-field scanners on the other hand produce lower quality images but to a fraction of the cost of their high-field counterpart. For low-field MRI, there is no well-established accuracy validation for quantitative cartilage estimates, but we show that differences between healthy and osteoarthritic populations are statistically significant using our cartilage volume and surface area estimates, which suggests that low-field MRI analysis can become a useful, affordable tool in clinical studies.
Introduction At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate cartilage longevity markers combining markers of breakdown, quantity, and quality.
The novel morphometric framework shows promise for use in clinical trials. The ability of the Cartilage Curvature quantification to detect the early stages of OA and the effectiveness of the focal thickness Q10 measure are particularly noteworthy. Furthermore, these results may indirectly support that low-field MRI may be a low-cost option for clinical trials.
These data demonstrate that the distribution of components of the articular matrix precedes erosion, as measured by cartilage homogeneity related to water concentration. We show that homogeneity was able to separate early OA from healthy individuals in contrast to traditional volume and JSW quantifications. These data suggest that cartilage homogeneity quantification may be able to quantify early biochemical changes in articular cartilage prior to cartilage loss and thereby provide better identification of patients for OA trials who may respond better to medicinal intervention of some treatments. In addition, this study supports the feasibility of using low-field MRI in clinical studies.
Osteoarthritis is characterized by the degeneration of the articular cartilage in joints. We have developed a fully automatic method for segmenting the articular cartilage in knee MR scans based on supervised learning. A binary approximate kNN classifier first roughly separates cartilage from background voxels, then a three-class classifier assigns one of three classes to each voxel that is classified as cartilage by the binary classifier. The resulting sensitivity and specificity are 90.0% and 99.8% respectively for the medial cartilage compartments. We show that an accurate automatic cartilage segmentation is achievable using a low-field MR scanner.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.